IRVINE, Calif., May 29, 2013 /PRNewswire/ -- Aviir, Inc. attended the AAPA's Impact 2013 conference in Washington DC, as guests of GUARDaHEART, a non-profit foundation focused on Heart Disease awareness, at the Walter E. Washington Convention Center on May 28-29. Aviir's Chief Executive Officer Douglas Harrington , MD, presented on May 28, in the Product Theatre.
"The presentation, 'Preventing Heart Disease: Identifying the Vulnerable Patient Before it is Too Late' discussed the clinical dilemma of at-risk patients being missed by current standard risk assessments, such as lipid panels and the Framingham ten year risk projection," said Dr. Harrington. "Fifty percent of heart attack patients have normal cholesterol levels, making early detection imperative to reducing risk before a cardiac event occurs and in halting disease progression early enough for the patient to improve their health."
During his presentation, Dr. Harrington also spoke about Aviir's MIRISK™ and MIRISK VP™ cardiac risk assessments. The MIRISK VP provides a net reclassification index improvement of 43 percent over Framingham, the current gold standard 10-year risk assessment, and was demonstrated in the MESA population. The test has applications across many medical specialties due to the prevalence of heart disease (750,000 new cases a year in the U.S. alone.).
Aviir has partnered with GUARDaHEART to promote Heart Disease awareness and prevention. Together, they have organized education events and fundraisers, and helped to make patient lifestyle modification a welcoming experience. GUARDaHEART's recommendations, activities, and events provide meaningful support and motivation to anyone interested in improving their heart health.
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests to assist in identifying patients who are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRISK and MIRISK VP assessments objectively identify, using a single blood draw, individuals who are at a high risk of experiencing a cardiac event over the next five years. Aviir's CLIA certified laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for heart health assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools to help improve the cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit www.aviir.com for more information.
GUARDaHEART is a non-profit foundation dedicated to raising awareness of Heart Disease prevention by spreading the word to guard your heart and save your life. Cardiovascular disease is the leading cause of death in the United States. The good news is if individuals know their risk and take the necessary steps, most cardiovascular disease can be prevented and reversed if detected early. Although heart disease is typically diagnosed in adulthood, its roots are often found in childhood. Compelling research has shown that plaque buildup in the arterial walls begins very early in life and progresses throughout life. Intervention strategies and healthy lifestyle modification to reduce heart disease risk should begin early when reversal of the process is easier, not later in life when the disease is more developed. GUARDaHEART Foundation also provides assistance for individuals who are unable to pay for cardiac risk assessments. Please visit www.guardaheart.org for more information.
For media inquiries, please contact:
Tamara York Public Relations, LLC
For Investor Relations, please contact:
Life Capital Partners
|SOURCE Aviir, Inc.|
Copyright©2012 PR Newswire.
All rights reserved